

Financial Summary

Results for FY2022 & Outlook for FY2023

Mitsui Chemicals, Inc.

<Remarks>

FY2022 indicates the period from April 1, 2022 to March 31, 2023.

FY2023 indicates the period from April 1, 2023 to March 31, 2024.

This summary contains forward-looking statements about the future plans, strategies, belief and performance of the Mitsui Chemicals Group as a whole and its individual consolidated companies. These forward-looking statements are not historical facts. They are expectations, estimates, forecasts and projections based on information currently available to the Mitsui Chemicals Group and are subject to a number of risks, uncertainties and assumptions, which, without limitation, include economic trends, fluctuations in foreign currency exchange rates, fluctuations in the price of raw materials, competition in markets where the Company is active, personal consumption, market demand, the tax system and other legislation. As such, actual results may differ materially from those projected and the Mitsui Chemicals Group cannot guarantee that these forward-looking statements are accurate or will be achieved.

May 12, 2023




























1. Results for FY2022 (April 1, 2022 – March 31, 2023)	
1) Trends of Key Market Indicators	... 1
2) Major Investment Projects, etc.	... 2
3) Consolidated Financial Highlights	... 3-4
4) Sales Revenue and Operating Income before Special Items by Business Segment (compared with FY2021 results)	... 5
5) Operating Income before Special Items and Business Overview by Business Segment	... 6-9
6) Non-recurring Items	... 10
7) Consolidated Statement of Financial Position	... 11
8) Consolidated Statement of Cash Flow	... 12
2. Outlook for FY2023 (April 1, 2023 – March 31, 2024)	
1) Highlights of Consolidated Financial Outlook	... 13-14
2) Sales Revenue and Operating Income before Special Items of Outlook by Business Segment (compared with FY2022)	... 15
3) Operating Income before Special Items and Business Overview by Business Segment	... 16-19
4) Performance Trends by Business Segment	... 20
5) Allocation of Resources	... 21
6) Shareholder Returns	... 22
7) Consolidated Statement of Cash Flow (Outlook)	... 23
3. Appendix	... 24-32

Please note that this document has been translated from the original Japanese into English for the convenience of our stakeholders. The information was originally provided in Japanese. If there is any discrepancy, the Japanese language version is the official document and is available on our Japanese language website.

1. Results for FY2022

(April 1, 2022 – March 31, 2023)

1) Trends of Key Market Indicators

		FY2022 YoY		FY2023 Outlook YoY	
Life & Healthcare Solutions	Ophthalmic lens materials market	Firm demand		Firm demand to continue	
	Agrochemicals market	Firm demand		Firm demand to continue	
Mobility Solutions	Automotive production (Global) *		+9%		+3%
	<ul style="list-style-type: none"> Japan North America China ASEAN Europe 	Recovered globally (except for Europe); varying degrees of recovery across regions	    	Global recovery expected (excluding China)	    
ICT Solutions	Semiconductor market	Weaker demand		Weaker demand to continue in 1H Gradual recovery expected in 2H	
	Smartphone market	Weaker demand		Weaker demand to continue in 1H Gradual recovery expected in 2H	
Basic & Green Materials	Market conditions				
	Phenol	Phenol, bisphenol A and acetone remained at low level due to continued easing of supply-demand balance			
	Bisphenol A				
	Acetone				
	TDI	Low level		Continued easing of supply-demand balance	
MDI			Market conditions expected to be stable		
	Cracker operating rates	Low		Expected to recover in 2H	

* Estimated from data by external information services

2) Major Investment Projects, etc.

Major Investment projects		Date	Capacity	FY21	FY22	FY23	FY24~
Life & Healthcare Solutions	Orthopedic surgery sector: Japan MDM Business and Capital Alliance	January.'22	-				
	Acquisition of agrochemicals business	January.'22	-				
	Acquisition of ophthalmic lens processing equipment maker	November.'22	-				
	Establishment of JV for nonwovens businesses @Japan	October.'23					
	Capacity expansion of MR™ High Refractive Index Ophthalmic Lens Material@Japan	October.'23	-				
Mobility Solutions	Establishment of new TAFMER™ plant@Singapore	FY24	120KT				
ICT Solutions	Establishment of new production facility for EUV pellicle@Japan	April.'21	-				
	Capacity expansion of cyclic olefin copolymers APEL™ @Japan	June.'22	+50%				
	Acquisition of pellicle business	July.'23	-				
	Capacity expansion of ICROS™ Tape@Taiwan	October.'23	3.8MMm ²				
Basic & Green Materials	Honshu Chemical Industry Co.: consolidated subsidiary	From Oct.'21	-				
	Capacity expansion of MDI, Kumho Mitsui Chemicals @Korea	July.'24	200Kt				
	New plant for high-performance PP@Japan	November.'24	200Kt				
	Investment in Apeiron Bioenergy to increase procurement of biomass raw materials	June.'22					
New business /New products	Establishment of CVC fund	July.'22	-				

Restructuring	Shutdown of PTA Production @Japa	August.'23	400Kt			Shutdown	
	Share transfer of phenols subsidiary@Singapore	March.'23				Share transfer	
	Optimization of TDI production capacity @Japan	July.'25	120Kt→50Kt				Optimization

Commercial operation launched in FY22

Investment decision made in FY22

3-1) Consolidated Financial Highlights


(Billions of Yen)

() Denotes a minus

Items	FY2021	FY2022	Increase (Decrease)	%
Sales revenue	1,612.7	1,879.5	266.8	17%
Operating income before special items	161.8	113.9	(47.9)	(30%)
(inc. Equity in earnings)	25.8	22.2	(3.6)	(14%)
Non-recurring items	(14.5)	15.1	29.6	-
Operating income	147.3	129.0	(18.3)	(12%)
Financial incomes/expenses	(6.0)	(11.7)	(5.7)	-
Income before taxes	141.3	117.3	(24.0)	(17%)
Net income attributable to owners of the parent	110.0	82.9	(27.1)	(25%)
Exchange rate (Yen/US\$)	112	135	23	
Domestic standard naphtha price (Yen/KL)	56,600	76,600	20,000	

3-2) Consolidated Financial Highlights (Operating Income before Special Items)

Factors	Comments	Profit/loss trigger
Volume	<ul style="list-style-type: none"> •Sales remained firm in vision care materials and agrochemicals. •Automotive applications recovered despite continued impact of global parts shortage. •Semiconductor applications decreased due to sluggish demand in semiconductor and smartphone markets. •Polyolefins and phenols decreased due to weaker demand. 	[+] [+] [-] [-]
Terms of trade	<ul style="list-style-type: none"> •Improvement in terms of trade driven by sales price revision and foreign exchange impact. •Overseas market conditions for bisphenol A weakened due to easing of supply-demand balance. •Inventory valuation gains (including time-lag effects of sales price formula) shrank due to decline in raw material prices from FY22 2Q. 	[+] [-] [-]
Costs, etc.	•Increase in costs driven by higher maintenance and repair expenses due to rise in construction-related material costs, and by investment of resources in new business and new product development and other initiatives.	[-]



4) Sales Revenue and Operating Income before Special Items by Business Segment

(compared with FY2021 results)

(Billions of Yen)


() Denotes a minus

Segment	Sales revenue			Operating income before special items			Breakdown		
	FY2021	FY2022	Incr. (Decr.)	FY2021	FY2022	Incr. (Decr.)	Volume	Terms of trade	Costs
Life & Healthcare Solutions	225.2	258.2	33.0	24.9	29.2	4.3	4.7	5.5	(5.9)
Mobility Solutions	432.7	521.6	88.9	33.2	49.3	16.1	2.3	26.0	(12.2)
ICT Solutions	207.1	235.7	28.6	30.2	23.8	(6.4)	(9.0)	8.0	(5.4)
Basic & Green Materials	737.1	849.0	111.9	77.8	17.8	(60.0)	(17.4)	(26.5)	(16.1)
Others	10.6	15.0	4.4	(4.3)	(6.2)	(1.9)	-	-	(1.9)
Total	1,612.7	1,879.5	266.8	161.8	113.9	(47.9)	(19.4)	13.0	(41.5)
Growth Domains*	865.0	1,015.5	150.5	88.3	102.3	14.0			

*Life & Healthcare, Mobility and ICT


5-1) Life & Healthcare Solutions: Operating Income before Special Items and Business Overview



	Business Overview of FY22 Movement of Operating Income before Special Items	Comments [+] denotes profit trigger [-] denotes loss trigger
Vision care	➡ •Sales remained firm •Decrease from unfavorable terms of trade, with rise in raw material prices more than offsetting increase from sales price revision	[+]Sales volume [-]Terms of trade
Nonwovens	➡ •Improvement in terms of trade driven by sales price revision	[-]Sales volume [+]Terms of trade
Oral care	➡ •Sales remained on par with the year-ago level •Higher fixed costs	[-]Costs
Agrochemicals	➡ •Sales remained firm •Improvement in terms of trade resulting from foreign exchange impact •Higher fixed costs due to sales increase	[+]Sales volume [+]Terms of trade [-]Costs




5-2) Mobility Solutions: Operating Income before Special Items and Business Overview




	Business Overview of FY22 Movement of Operating Income before Special Items	Comments [+] denotes profit trigger [-] denotes loss trigger
Elastomers	<ul style="list-style-type: none"> • Sales of solar cell encapsulants remained firm • Improved terms of trade resulting from sales price revision, foreign exchange impact and shift to high value-added products 	[+] Terms of trade [-] Costs
Composite materials (PP compounds, Performance compounds)	<ul style="list-style-type: none"> • Sales recovered in automotive applications • Improvement in terms of trade resulting from sales price revision and foreign exchange impact 	[+] Sales volume [+] Terms of trade [-] Costs
Solutions business	<ul style="list-style-type: none"> • Sales on par with the year-ago level due to continued decrease in orders received 	-




	Business Overview of FY22 Movement of Operating Income before Special Items	Comments [+] denotes profit trigger [-] denotes loss trigger
Semiconductor & Optical materials	 <ul style="list-style-type: none"> •Sales were down, with sluggish demand in semiconductor and smartphone markets more than offsetting firm sales of EUV pellicles •Improvement in terms of trade resulting from foreign exchange impact •Higher fixed costs due to operation of new plant (APEL™) 	[-]Sales volume [+]Terms of trade [-]Costs
Industrial films	 <ul style="list-style-type: none"> •Sales were down due to sluggish semiconductor demand •Improvement in terms of trade resulting from foreign exchange impact 	[-]Sales volume [+]Terms of trade



5-4) Basic & Green Materials: Operating Income before Special Items and Business Overview

	Business Overview of FY22 Movement of Operating Income before Special Items	Comments [+] denotes profit trigger [-] denotes loss trigger
Petrochemicals	 <ul style="list-style-type: none"> •Sales were down due to weaker demand •Inventory valuation gains (including time-lag effects of sales price formula) shrank due to decline in raw material prices from FY22 2Q 	[-]Sales volume [-]Inventory valuation [-]Costs
Basic chemicals	 <ul style="list-style-type: none"> •Sales were down due to weaker demand •Overseas market conditions for bisphenol A weakened due to easing of supply-demand balance 	[-]Sales volume [-]Terms of trade [-]Costs [-]Equity in earnings
Polyurethanes	 <ul style="list-style-type: none"> •Increase in equity in earnings 	[-]Sales volume [+]Equity in earnings

() Denotes a minus



6) Non-recurring Items

(Billions of Yen)

() Denotes a minus

Items	FY2021	FY2022	Incr. (Decr.)
Loss (gain) on sales and disposal of non-current assets	(1.4)	(2.0)	(0.6)
Impairment loss	(16.2)	(7.5)	8.7
Others	3.1	24.6	21.5
Non-recurring items total	(14.5)	15.1	29.6

7) Consolidated Statement of Financial Position

(Billions of Yen)

() Denotes a minus

Items	End of Mar. 2022	End of Mar.2023	Incr. (Decr.)	Items	End of Mar. 2022	End of Mar.2023	Incr. (Decr.)
Current assets	1,033.5	1,094.3	60.8	Liabilities	1,127.9	1,184.9	57.0
Cash and cash equivalents	181.2	186.3	5.1	Operating payables	174.8	164.3	(10.5)
Operating receivables	370.4	352.2	(18.2)	Interest-bearing liabilities	715.1	794.7	79.6
Inventories	369.0	441.9	72.9	Other liabilities	238.0	225.9	(12.1)
Other current assets	112.9	113.9	1.0				
Non-current assets	901.5	973.9	72.4	Equity	807.1	883.3	76.2
Property, plant and equipment & right-of-use assets	553.6	600.9	47.3	Equity attributable to owners of the parent	712.7	786.8	74.1
Goodwill and Intangible assets	63.3	67.5	4.2	Non-controlling interests	94.4	96.5	2.1
Other non-current assets	284.6	305.5	20.9				
Total	1,935.0	2,068.2	133.2	Total	1,935.0	2,068.2	133.2

8) Consolidated Statement of Cash Flow

(Billions of Yen)

() Denotes a minus

Items	FY2021	FY2022	Incr. (Decr.)
I . Cash flows from operating activities (a)	92.6	101.2	8.6
II . Cash flows from investing activities (b)	(205.2)	(106.3)	98.9
Free cash flows (a)+(b)	(112.6)	(5.1)	107.5
III . Cash flows from financing activities	89.2	2.5	(86.7)
IV . Others	8.6	7.7	(0.9)
Net incr.(decr.) in cash and cash equivalents	(14.8)	5.1	19.9

2. Outlook for FY2023

(April 1, 2023 – March 31, 2024)

Mitsui Chemicals, Inc. has changed its business segment structure effective April 1, 2022. Results for FY2021 and prior years based on the new business segments are reference figures which have been prepared for the purpose of comparison with figures for FY2022 and onward.

1-1) Highlights of Consolidated Financial Outlook

(Billions of Yen)

Items	FY2022	FY2023 Outlook	Incr.(Decr.)	
			Full Year	%
Sales revenue	1,879.5	1,900.0	20.5	1%
Operating income before special items	113.9	150.0	36.1	32%
Non-recurring items	15.1	(5.0)	(20.1)	—
Operating income	129.0	145.0	16.0	12%
Financial income/expenses	(11.7)	(5.0)	6.7	—
Income before taxes	117.3	140.0	22.7	19%
Net income attributable to owners of the parent	82.9	100.0	17.1	21%

Exchange rate (Yen/US\$)

135

135

0

Domestic standard naphtha price (Yen/KL)

76,600


72,000

(4,600)

1-2) Highlights of Consolidated Financial Outlook (Operating Income before Special Items)

Factors	Comments	Profit/loss trigger
Volume	• Sales for vision care materials and agrochemicals expected to remain firm.	[+]
	• Automotive applications expected to recover; solar cell encapsulants expected to remain firm.	[+]
	• Polyolefins expected to increase due to demand recovery.	[+]
	• Overall sales volume expected to increase due to demand recovery.	[+]
Terms of trade	• Sales price revisions in response to rise in utility, logistics, and other costs.	[+]
	• Removal of impact of inventory valuation gains (including time-lag effects of sales price formula) due to rise in raw material prices in FY22.	[-]
Costs, etc.	• Increase in labor costs due to headcount growth to pursue sales and business expansion.	[-]
	• Increase in costs driven by higher maintenance and repair expenses due to rise in construction-related material costs, and by investment of resources in new business and new product development and other initiatives.	[-]
	• Increase in costs associated with circular economy and digital transformation initiatives.	[-]
	• Improvement in profitability from business restructuring.	[+]

(-) Denotes a minus



2) Sales Revenue and Operating Income before Special Items of Outlook by Business Segment

(compared with FY2022)

(Billions of Yen)


() Denotes a minus

Segment	Sales revenue			Operating income before special items			Breakdown		
	FY2022 (a)	FY2023 Outlook (b)	Incr.(Decr.) (b)-(a)	FY2022 (c)	FY2023 Outlook (d)	Incr.(Decr.) (d)-(c)	Volume	Terms of trade	Costs
Life & Healthcare Solutions	258.2	284.0	25.8	29.2	34.0	4.8	10.0	2.5	(7.7)
Mobility Solutions	521.6	558.0	36.4	49.3	54.0	4.7	18.0	(4.0)	(9.3)
ICT Solutions	235.7	271.0	35.3	23.8	33.0	9.2	10.0	4.5	(5.3)
Basic & Green Materials	849.0	770.0	(79.0)	17.8	35.0	17.2	8.5	9.0	(0.3)
Others	15.0	17.0	2.0	(6.2)	(6.0)	0.2	-	-	0.2
Total	1,879.5	1,900.0	20.5	113.9	150.0	36.1	46.5	12.0	(22.4)
Growth Domains *	1,015.5	1,113.0	97.5	102.3	121.0	18.7			

*Life & Healthcare, Mobility and ICT


3-1) Life & Healthcare Solutions: Operating Income before Special Items and Business Overview

	Business Overview of FY23 (Outlook): Movement of Operating Income before Special Items		Comments [+] denotes profit trigger [-] denotes loss trigger
Vision care	➔	<ul style="list-style-type: none"> • Sales staying firm • Improvement in terms of trade driven by sales price revisions in FY22 • Higher fixed costs due to operation of new plant (MR™) 	[+] Sales volume [+] Terms of trade [-] Costs
Nonwovens	➔	<ul style="list-style-type: none"> • Sales increase expected from establishment of joint venture 	[+] Sales volume
Oral care	➔	<ul style="list-style-type: none"> • Sales staying firm • Increase in labor costs due to headcount growth to pursue sales expansion 	[+] Sales volume [-] Costs
Agrochemicals	➔	<ul style="list-style-type: none"> • Sales staying firm • Increase in registration maintenance fees and research expenses such as laboratory costs, driven by sales growth 	[+] Sales volume [-] Costs



3-2) Mobility Solutions: Operating Income before Special Items and Business Overview


	Business Overview of FY23 (Outlook): Movement of Operating Income before Special Items	Comments [+] denotes profit trigger [-] denotes loss trigger
Elastomers	<ul style="list-style-type: none"> • Sales increase driven by recovery in automotive applications and firm demand for solar cell encapsulants • Higher fixed costs due to maintenance and repair expenses, etc. 	[+] Sales volume [-] Equity in earnings [-] Costs
Composite materials (PP compounds, Performance compounds)	<ul style="list-style-type: none"> • Sales increase driven by recovery in automotive applications • Removal of gains from time-lag effects of sales price formula in FY22 2H • Increase in labor costs due to headcount growth to pursue sales expansion 	[+] Sales volume [-] Terms of trade [-] Costs
Solutions business	<ul style="list-style-type: none"> • Increase in orders received driven by recovery in automotive markets • Increase in labor costs due to headcount growth to pursue sales expansion 	[+] Sales volume [-] Costs



3-3) ICT Solutions: Operating Income before Special Items and Business Overview


	Business Overview of FY23 (Outlook): Movement of Operating Income before Special Items	Comments [+] denotes profit trigger [-] denotes loss trigger
Semiconductor & Optical materials	<ul style="list-style-type: none"> • EUV pellicle sales expected to remain firm; sales increase from acquisition of pellicle business • Improvement in terms of trade through development of higher value-added applications of products • Increase in development expenses and other costs for sales expansion 	[+]Sales volume [+]Terms of trade [-]Costs
Coating & engineering materials	<ul style="list-style-type: none"> • Sales growth of high value-added products • Increase in development expenses and other costs for sales expansion 	[+]Sales volume [+]Terms of trade [-]Costs
Industrial films	<ul style="list-style-type: none"> • Sales increase expected, with semiconductor market projected to recover in FY23 2H 	[+]Sales volume

(-) Denotes a minus




3-4) Basic & Green Materials: Operating Income before Special Items and Business Overview

	Business Overview of FY23 (Outlook): Movement of Operating Income before Special Items	Comments [+] denotes profit trigger [-] denotes loss trigger
Petrochemicals	<ul style="list-style-type: none"> • Sales volume expected to increase due to demand recovery • Improvement in terms of trade driven by sales price revisions • Removal of impact of inventory valuation gains (including time-lag effects of sales price formula) due to rise in raw material prices in FY22 	[+] Sales volume [+] Terms of trade [-] Inventory valuation
Basic chemicals	<ul style="list-style-type: none"> • Sales volume expected to increase due to demand recovery • Improvement in terms of trade driven by sales price revisions • Improvement in profitability from business restructuring 	[+] Sales volume [+] Terms of trade
Polyurethanes	<ul style="list-style-type: none"> • Sales volume expected to increase due to demand recovery • Decrease in equity in earnings 	[+] Sales volume [-] Equity in earnings



4) Performance Trends by Business Segment




*Life & Healthcare, Mobility and ICT

5) Allocation of Resources


Capital expenditure

(Billions of Yen)



R&D expenses

(Billions of Yen)




6) Shareholder returns

● FY23 Dividend Outlook

Interim	Year-end	Full Year		
70	+	70	=	140
Yen/Share		Yen/Share		Yen/Share

- ✓ Target dividends on equity: 3.0% or more
- ✓ Stable and continuous dividend
- ✓ Flexible acquisition of treasury stock
- ✓ Target total return ratio: 30% or more



	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23 Outlook
Dividend(yen)	40*	70*	90*	100	100	100	120	120	140
Acquisition of treasury stock (billion yen)	—	—	5	10	10	—	10	10	
DOE(%)	2.0	3.4	3.7	3.7	3.6	3.4	3.5	3.1	
Total return ratio(%)	35	22	32	39	77	34	30	40	

7) Consolidated Statement of Cash Flow (Outlook)

(Billions of Yen)

Items	FY2022	FY2023 Outlook	Incr.(Decr.)
I . Cash flows from operating activities (a)	101.2	153.0	51.8
II . Cash flows from investing activities (b)	(106.3)	(138.0)	(31.7)
Free cash flows (a)+(b)	(5.1)	15.0	20.1
III . Cash flows from financing activities	2.5	(23.0)	(25.5)
IV . Others	7.7	0.0	(7.7)
Net incr.(decr.) in cash and cash equivalents	5.1	(8.0)	(13.1)

3. Appendix

- 1) Trends in Product Prices
- 2) Sales Revenue Increase/Decrease (Year on Year) by Business Segment
- 3) Sales Revenue and Operating Income before Special Items by Business Segment (by Quarter)
- 4) Outline of Business Segments
- 5) Data Highlights

1) Trends in Product Prices

(Naphtha prices are Domestic Standard Naphtha Price)

(PE, PP, PH, BPA(Japan) : Change in Prices and Raw Materials Prices in Japan / BPA(China), PTA, TDI : Chinese Market Price)

(ACP) : Asian contract price

Year	2020			2021				2022				2023
Month	Apr.-Jun.	Jul.-Sep.	Oct.-Dec.	Jan.-Mar.	Apr.-Jun.	Jul.-Sep.	Oct.-Dec.	Jan.-Mar.	Apr.-Jun.	Jul.-Sep.	Oct.-Dec.	Jan.-Mar.
Naphtha (Yen/KL)	24,900	30,200	31,300	38,800	47,700	53,500	60,700	64,600	86,100	81,400	72,500	66,500
PE (Yen/KG)	about (30)			about +20		about +10	about +30	about +30	about +15	about (10)	about (15)	about (10)
PP (Yen/KG)	about (30)			about +20		about +10	about +30	about +30	about +15	about (10)	about (15)	about (10)
PH (Formula Price) (Yen/KG)												
BZ(ACP) (US\$/T)	\$360	\$440	\$490	\$720	\$930	\$1,030	\$970	\$1,030	\$1,230	\$1,120	\$880	\$930
BPA(Japan) (Yen/KG)	(15) From Jun.				+60 From Apr.	+35 From Sep.		+20 From Mar.	+32 From Apr. +38 From Jun.		(14) From Dec.	(17) From Mar.
	negotiation based on BZ price and BPA market price											
BPA(China) (US\$/T)	\$1,210	\$1,290	\$1,990	\$2,630	\$3,230	\$3,320	\$2,480	\$2,340	\$2,060	\$1,580	\$1,450	\$1,300
PTA (US\$/T)	\$420	\$440	\$450	\$600	\$660	\$710	\$700	\$830	\$950	\$840	\$760	\$780
PX(ACP) (US\$/T)	\$500	\$550	\$560	\$770	\$860	\$920	\$890	\$1,090	\$1,260	\$1,090	\$980	\$1,030
TDI (US\$/T)	\$1,330	\$1,580	\$2,330	\$2,150	\$2,040	\$1,900	\$2,200	\$2,610	\$2,770	\$2,320	\$2,410	\$2,430

2-1) Sales Revenue Increase/Decrease (Year on Year) by Business Segment

Life & Healthcare



() Denotes a minus


- **Volume +16.5 billion yen**
 - Firm sales of vision care materials and agrochemicals.
- **Prices +16.5 billion yen**
 - Increase from sales price revision in line with rise in raw material prices, and foreign exchange impact.

Mobility



- **Volume +11.8 billion yen**
 - Sales recovered in automotive applications; sales of solar cell encapsulants were firm.
- **Prices +77.1 billion yen**
 - Increase from sales price revision in line with rise in raw material prices, foreign exchange impact, etc.

2-2) Sales Revenue Increase/Decrease (Year on Year) by Business Segment




() Denotes a minus

➤ **Volume (15.7) billion yen**

- Sales of semiconductor applications decreased.

➤ **Prices +44.3 billion yen**

- Increase from sales price revision in line with rise in raw material prices, and foreign exchange impact.



➤ **Volume (53.5) billion yen**

- Sales of polyolefins and phenols decreased.

➤ **Prices +165.4 billion yen**

- Increase from sales price revision in line with rise in raw material prices.

3) Sales Revenue and Operating Income before Special Items by Business Segment (by Quarter)

(Billions of Yen)



() Denotes a minus

Segment	Sales revenue							
	FY2021				FY2022			
	Apr-Jun	Jul-Sep	Oct-Dec	Jan-Mar	Apr-Jun	Jul-Sep	Oct-Dec	Jan-Mar
Life & Healthcare Solutions	52.3	50.5	56.1	66.3	58.7	63.4	64.7	71.4
Mobility Solutions	100.9	98.5	112.0	121.3	120.6	134.8	135.4	130.8
ICT Solutions	50.6	51.1	53.6	51.8	59.2	59.0	61.4	56.1
Basic & Green Materials	163.3	171.2	197.1	205.5	234.3	214.0	212.2	188.5
Others	3.5	1.6	2.8	2.7	3.3	3.8	4.1	3.8
Total	370.6	372.9	421.6	447.6	476.1	475.0	477.8	450.6



Segment	Operating income before special items							
	FY2021				FY2022			
	Apr-Jun	Jul-Sep	Oct-Dec	Jan-Mar	Apr-Jun	Jul-Sep	Oct-Dec	Jan-Mar
Life & Healthcare Solutions	6.4	5.3	6.6	6.6	6.2	7.6	7.8	7.6
Mobility Solutions	9.6	6.7	7.7	9.2	9.5	13.9	15.5	10.4
ICT Solutions	9.2	7.5	8.5	5.0	9.2	5.8	8.0	0.8
Basic & Green Materials	27.0	22.6	17.9	10.3	20.8	6.5	2.5	(12.0)
Others	(0.3)	0.3	(0.7)	(3.6)	(1.1)	(0.8)	(1.1)	(3.2)
Total	51.9	42.4	40.0	27.5	44.6	33.0	32.7	3.6

*Segment-by-segment breakdown figures for FY2021 operating income before special items based on the new business segment structure introduced on April 1, 2022 have been revised from the previous figures announced on May 13, 2022.



4) Outline of Business Segments

Segment	Businesses	Main Products
Life & Healthcare Solutions	Vision Care Materials, Personal Care Materials, Nonwovens, Oral Care, Agrochemicals and Medical Business Development	Ophthalmic lens materials (MR™, Do Green™), Medical materials (taurine), Nonwovens (SYNTEX™, AIRYFA™, TEKNOROTE™), Oral care materials (restoratives, adhesives, digital equipment), Agrochemicals (dinotefuran, TENEBENAL™)
Mobility Solutions	Elastomers, Composite Materials and Mobility Solutions	TAFMER™, Mitsui EPT™, LUCANT™, PP compounds, Performance compounds (ADMER™, MILASTOMER™, ARLEN™)  
ICT Solutions	Semiconductor & Optical Materials, Coating & Engineering Materials, Performance Films & Sheets and ICT Materials	Mitsui PELLICLE™ (ArF, KrF, EUV), APEL™, TPX™, Semiconductor gas, High-performance food packaging materials (sealants, adhesives, coating agents, eco-friendly packaging), Industrial films (ICROS™ Tape, SP-PET™), Packaging films (T.U.X™)
Basic & Green Materials	Phenols, PTA&PET, Industrial Chemicals, Sustainable Feedstocks, Polyolefins, Licensing, Polyurethanes and Green Sustainable Chemicals	Phenol, Bisphenol A, Acetone, PTA, PET, EO, Hydroquinone, Ammonia, Exhaust gas reduction agent (AdBlue™*), Polyolefins, TDI, MDI <small>*AdBlue is a trademark of the VDA (Verband der Automobilindustrie).</small>





5-1) Data Highlights



*1. Consolidated balance sheet as of FY2017 is restated to reflect changes in presentation from including an impact of "Partial Amendments to Accounting Standard for Tax Effect Accounting".



5-2) Data Highlights




5-3) Data Highlights

Sales revenue and sales revenue ratios of Blue Value™ products

Environmental contributions - Blue Value™


Blue Value™ products sales revenue ratio: %
 Blue Value™ products sales revenue : ■




Sales revenue and sales revenue ratios of Rose Value™ products

QOL improvements - Rose Value™


Rose Value™ products sales revenue ratio: %
 Rose Value™ products sales revenue : ■



Sales revenue composition by business segment of Blue Value™ and Rose Value™ products (FY2022)



- Life & Healthcare Solutions
- Mobility Solutions
- ICT Solutions
- Basic & Green Materials




5-4) Data Highlights


Sales revenue and sales revenue ratios of Blue Value™ and Rose Value™ products in each segment

■ Blue Value™ sales revenue
 ● Blue Value™ sales revenue ratio (%)
 ■ Rose Value™ sales revenue
 ● Rose Value™ sales revenue ratio (%)

Life & Healthcare Solutions



Mobility Solutions



ICT Solutions



Basic & Green Materials



Chemistry for Sustainable World



Mitsui Chemicals

Challenge Diversity One Team